A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia.
about
The second decade of 3C technologies: detailed insights into nuclear organizationQuantitative Trait Loci Identify Functional Noncoding Variation in CancerMinor Loops in Major Folds: Enhancer-Promoter Looping, Chromatin Restructuring, and Their Association with Transcriptional Regulation and DiseaseThe search for cis-regulatory driver mutations in cancer genomesTranscriptional network control of normal and leukaemic haematopoiesisMechanisms Underlying the Selection and Function of Macrophage-Specific EnhancersChromatin signatures of cancerEmerging concepts of epigenetic dysregulation in hematological malignanciesMaking Sense of the Tangle: Insights into Chromatin Folding and Gene RegulationStructural and functional diversity of Topologically Associating DomainsThe mechanisms behind the therapeutic activity of BET bromodomain inhibitionControl of cell identity genes occurs in insulated neighborhoods in mammalian chromosomesdbSUPER: a database of super-enhancers in mouse and human genomeBCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesisAn oncogenic MYB feedback loop drives alternate cell fates in adenoid cystic carcinoma.TCGA Workflow: Analyze cancer genomics and epigenomics data using Bioconductor packagesEpigenetics in normal and malignant hematopoiesis: An overview and update 2017.Enhancers and chromatin structures: regulatory hubs in gene expression and diseases.Super-Enhancers and Broad H3K4me3 Domains Form Complex Gene Regulatory Circuits Involving Chromatin Interactions.RUNX1-ETO and RUNX1-EVI1 Differentially Reprogram the Chromatin Landscape in t(8;21) and t(3;21) AML.Somatic chromosomal engineering identifies BCAN-NTRK1 as a potent glioma driver and therapeutic target.Molecular basis of crosstalk between oncogenic Ras and the master regulator of hematopoiesis GATA-2Convergence of developmental and oncogenic signaling pathways at transcriptional super-enhancers.Identification of focally amplified lineage-specific super-enhancers in human epithelial cancers.Insulated Neighborhoods: Structural and Functional Units of Mammalian Gene Control.Pan-cancer analysis of somatic copy-number alterations implicates IRS4 and IGF2 in enhancer hijacking.GATA2 deficiency-associated bone marrow disorder differs from idiopathic aplastic anemia.Mutational spectrum of myeloid malignancies with inv(3)/t(3;3) reveals a predominant involvement of RAS/RTK signaling pathways.GATA2 deficiency.Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms.CRISPR reveals a distal super-enhancer required for Sox2 expression in mouse embryonic stem cells.Haematopoietic and immune defects associated with GATA2 mutation.Epigenetic Determinants of Erythropoiesis: Role of the Histone Methyltransferase SetD8 in Promoting Erythroid Cell Maturation and SurvivalGATA2 rs2335052 Polymorphism Predicts the Survival of Patients with Colorectal Cancer.BET Bromodomain Inhibition Suppresses the Function of Hematopoietic Transcription Factors in Acute Myeloid Leukemia.Functional annotation of HOT regions in the human genome: implications for human disease and cancer.4C-ker: A Method to Reproducibly Identify Genome-Wide Interactions Captured by 4C-Seq Experiments.Deficiency of the ribosome biogenesis gene Sbds in hematopoietic stem and progenitor cells causes neutropenia in mice by attenuating lineage progression in myelocytes.Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors.BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells
P2860
Q26747370-949F6650-19CD-44E0-93C2-E669EE73FC37Q26764745-3EC5BAFD-B4F3-4FF2-A042-64AC386216D3Q26775145-CF2E97C6-F420-4D6C-BA3B-8ABFE1D6EF8BQ26781886-7418AE0B-18AB-422D-956E-0866E9A534E3Q27005940-4699AFBF-D3ED-4A1C-9CCA-B9C6F525D76AQ27006789-02ADFAB8-05C8-430F-A96D-88903ECDB4D7Q27024162-0FDA7E5F-BA8C-406C-8E9A-8745B5F9B20FQ28074522-429D8AB0-CC24-49CB-B3F0-0B393EF18255Q28075462-7B44E049-6BD8-4B95-A358-9D88DB96E6BDQ28088652-35DE90FD-013B-4F14-9594-D39BD0235C42Q28241504-36686039-7B0C-4773-9509-6C705745B411Q28249527-98C17C8D-4955-4AB7-8032-6FB542418083Q28603137-B824C557-9BC2-48A9-9B52-8338A7742132Q28607483-5ACF234B-ED0A-4614-9DD2-EBB526F65063Q30277644-DD2BD1BC-A1F7-4B72-B070-A607A658D6E6Q31165459-645B521E-7EA4-4193-ABC9-011989510C7CQ33607609-13BF2BB9-8930-4041-92C9-6342BC2DB118Q33613467-62E1E02E-302D-47CE-B930-057DDF139FE4Q33708447-9E3BA1A6-6E53-4117-B3C1-ECFAB8D55CD9Q33759034-2EA83B3C-31E5-4B72-A75C-901FCEE9126AQ33899971-8E6BEEF6-F4FE-4EE0-932B-282D1F72620EQ34343246-2FB3858F-7DA9-4FF8-B191-04CC2094C657Q34468271-8F87174C-434E-4706-91B9-E96225974012Q34504751-94B4B132-1123-4500-9D06-01662CD1C6E2Q34545070-B9B2B70C-83C1-4242-AA2C-EEABE231760CQ34545220-E823B490-1E82-45DF-9F45-AB7D5644A1C3Q34802461-2DABB11F-D4AC-459C-A0C8-BD7C28061307Q35102301-CB934284-32D1-49EE-96ED-E0C52BA47F06Q35127953-5948F861-2609-47FB-AD3D-73E7802156E9Q35407362-DC20E7A8-F2E2-4734-9C7C-E0BB4D72312EQ35500089-2A04F8BF-7ADE-49FF-8362-5BECBE625AFDQ35535835-31ABC8C6-74FE-4FD5-9057-8F483E895127Q35626111-5DCD5BEF-BC10-4F52-AC43-40555391DC5CQ35750225-F4F6BF4E-BDC3-4033-969F-C9E16E56798AQ35762941-8F7ED694-4D09-4BBB-BFD1-6E7848A3756DQ35784256-1783E772-E873-443F-960A-0887EE7AE367Q35944282-F0DC2D3B-AA6C-4436-AED2-902F4BF2BDA4Q36115659-074F9C6E-7A4D-4DE5-B9D3-0571D41638D4Q36219652-AC2300D3-460A-4CC3-92E9-8A9B046635CDQ36232141-AFCDBF21-BF43-4A08-9A2D-02ED537FEA86
P2860
A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia.
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
A single oncogenic enhancer re ...... ATA2 deregulation in leukemia.
@ast
A single oncogenic enhancer re ...... ATA2 deregulation in leukemia.
@en
A single oncogenic enhancer re ...... ATA2 deregulation in leukemia.
@nl
type
label
A single oncogenic enhancer re ...... ATA2 deregulation in leukemia.
@ast
A single oncogenic enhancer re ...... ATA2 deregulation in leukemia.
@en
A single oncogenic enhancer re ...... ATA2 deregulation in leukemia.
@nl
prefLabel
A single oncogenic enhancer re ...... ATA2 deregulation in leukemia.
@ast
A single oncogenic enhancer re ...... ATA2 deregulation in leukemia.
@en
A single oncogenic enhancer re ...... ATA2 deregulation in leukemia.
@nl
P2093
P50
P1433
P1476
A single oncogenic enhancer re ...... ATA2 deregulation in leukemia.
@en
P2093
Britta A M Bouwman
Claudia Erpelinck
Elwin J Rombouts
Eric M J Bindels
H Berna Beverloo
James E Bradner
Kirsten van Lom
Marije Havermans
Mark van Duin
Mathijs A Sanders
P304
P356
10.1016/J.CELL.2014.02.019
P407
P577
2014-04-03T00:00:00Z